Version history

{
  "session_id": "sess_SDA-2026-04-28-microglial-priming-causal-nd_task_66f1207e_ctx",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "Theorist position for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference\n\nContext: Analytic arms: cell-type-specific MR, scVelo trajectory, longitudinal CSF Granger causality. Exposure genes: TREM2, CX3CR1, C1QA, C1QB, C1QC. Diseases: AD, PD, ALS, MS.\n\nPrimary claim: microglial priming as a partially upstream causal node rather than a pure disease-stage correlate is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this causal inference analysis, the debate should preserve the named strata and entities: TREM2, CX3CR1, C1QA, C1QB, C1QC.\n\nThe constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.\n\nFor the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.",
  "tokens_used": "408",
  "persona_id": "persona-theorist"
}